Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Viral persistence

Why Theraclone remains confident in anti-flu mAb despite Phase II miss

Theraclone Sciences Inc. was to present data Sept. 8 showing TCN-032 missed the primary endpoint in a Phase IIa influenza viral challenge study. However, the company says the endpoint, rather than the mAb, was the problem.

Based on a trend of symptomatic improvement and significant improvements on secondary endpoints including viral shedding and clinical measures, Theraclone hopes to get a government contract to fund the rest of the Phase II program, with an initial focus on seriously ill hospitalized flu patients.

TCN-032 is a human mAb against

Read the full 856 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers